Irinotecan in chemotherapy of advanced colorectal cancer

Krzysztof Leśniewski-Kmak

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2006
vol. 10

Send email

Copy url:

abstract:

Irinotecan in chemotherapy of advanced colorectal cancer

Krzysztof Leśniewski-Kmak

Współcz Onkol (2006) vol. 10; 3 (133-135)

Online publish date: 2006/04/12

View full text Get citation

Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin, which effectiveness and toxicity have been extensively investigated in colorectal cancer (crc) and in this type of neoplasm it has wide application. Promising outcomes of early trials with CPT-11 and crc patients have been confirmed in randomized trials. In 5-fu-refractory crc patients, irinotecan showed advantage over best supportive care and infusions of 5-fu. Trials with CPT-11 in the first line treatment of crc also reported highest efficacy of this agent than 5-fu and leucovorin. Several trials have been conducted with irinotecan in schedules with targeted therapy agents and others, like oxaliplatin and oral precursor of 5-fu, capecytabine. An early trial with the oral form of irinotecan has also been reported.

keywords:

Irinotecan in chemotherapy of advanced colorectal cancer

Krzysztof Leśniewski-Kmak

irinotecan, chemotherapy, colorectal cancer